ArticleFood science & nutrition2026
Virgin Coconut Oil Attenuates Diabetic Kidney Disease via Gut Microbiota-Metabolism-Inflammation Axis Modulation in Type 2 Diabetic Mice.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) poses a significant global health challenge, necessitating novel therapeutic interventions. Virgin coconut oil (CO), rich in medium-chain fatty acids (MCFAs), has emerging metabolic benefits, but its renoprotective potential and mechanistic basis remain unexplored. This study aimed to investigate the therapeutic effects of CO on DKD and elucidate its underlying molecular mechanisms through a multimodal approach. Network pharmacology and molecular docking were employed to predict CO's bioactive targets and pathways. Experimental validation was performed in a high-fat diet/streptozotocin-induced type 2 diabetic mouse model, with CO administered for 12 weeks. Systemic metabolic parameters (glucose, BUN, Scr, lipid profiles) and renal function were evaluated. Renal histopathology (H&E, Masson staining), inflammatory markers (TNF-α, IL-6), oxidative stress indicators (GSH-Px, SOD, MDA), and fibrosis markers (TGF-β, Collagen IV) were quantified. Gut microbiota composition (16S rRNA sequencing) and serum metabolomic profiling (LC-MS) were analyzed to identify systemic mechanisms. Computational analysis identified octanoic acid and decanoic acid of MCFAs as principal bioactive components targeting PPARα/γ and IL-1β, modulating PPAR signaling and oxidative phosphorylation. In vivo, CO significantly ameliorated hyperglycemia, reduced uremic toxins, and improved lipid metabolism. Renal benefits included attenuated inflammation, restored redox balance, and suppressed fibrosis. Gut microbiota restructuring revealed decreased pro-inflammatory
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.